Bio-Path (NASDAQ:BPTH) Stock Passes Above 200 Day Moving Average of $14.16

Bio-Path Holdings Inc (NASDAQ:BPTH) crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $14.16 and traded as high as $12.32. Bio-Path shares last traded at $11.94, with a volume of 18,631 shares.

Several analysts have recently weighed in on BPTH shares. ValuEngine raised shares of Bio-Path from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. HC Wainwright reissued a “buy” rating and issued a $28.00 price target on shares of Bio-Path in a report on Friday, August 16th.

The company has a quick ratio of 18.01, a current ratio of 18.01 and a debt-to-equity ratio of 0.02. The firm has a market cap of $34.39 million, a price-to-earnings ratio of -0.82 and a beta of 3.16. The business’s fifty day moving average is $13.17 and its two-hundred day moving average is $14.16.

Bio-Path (NASDAQ:BPTH) last issued its quarterly earnings results on Thursday, August 15th. The company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.27). Research analysts forecast that Bio-Path Holdings Inc will post -3.2 EPS for the current year.

Institutional investors have recently modified their holdings of the stock. Morgan Stanley increased its holdings in shares of Bio-Path by 19,858.0% during the second quarter. Morgan Stanley now owns 19,958 shares of the company’s stock worth $267,000 after buying an additional 19,858 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Bio-Path by 10.3% in the second quarter. Vanguard Group Inc. now owns 27,925 shares of the company’s stock valued at $374,000 after purchasing an additional 2,601 shares in the last quarter. BlackRock Inc. increased its holdings in shares of Bio-Path by 17.5% in the second quarter. BlackRock Inc. now owns 46,879 shares of the company’s stock valued at $628,000 after purchasing an additional 6,978 shares in the last quarter. Finally, Gainplan LLC acquired a new stake in shares of Bio-Path in the first quarter valued at approximately $204,000. 8.93% of the stock is owned by institutional investors and hedge funds.

About Bio-Path (NASDAQ:BPTH)

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.

Featured Story: What is required to own or exchange cryptocurrency?

Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.